No Data
CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland
Express News | JPMorgan Chase & Co's Long Position in Shares of Beigene Increases to 10.94% on Dec 9 From 9.92% - HKEX
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
CSPC PHARMA and BEIGENE have entered into an exclusive licensing agreement for SYH2039.
CSPC PHARMA (01093) announced that the group has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH (BEIGENE) for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as for any Pharmaceuticals composed of or containing this compound for development, manufacturing, and commercialization on a Global scale. Under the agreement, and in accordance with its terms and conditions, the group agrees to grant BEIGENE exclusive rights for the Global development, manufacturing, and commercialization of that compound and product. The group will receive a total of 1.50.
CSPC Pharmaceutical Partners With BeiGene on Innovative Cancer Drug
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
守株待鹅 : Goddess, which one are you Bullish on?